The recommendation statements are as follows:
- All patients should have cross sectional imaging (CT scan or MRI) and bone scan
- The standard therapy is radical prostatectomy OR radiation therapy with androgen deprivation therapy
- Watchful waiting should only be considered in asymptomatic men with short life expectancies
- Primary ADT should only be offered in symptomatic men with short life expectancy
- Active surveillance is not recommended
- Focal therapies including HIFU and cryoablation are not recommended
- Clinicians should consider referral to genetic counseling for patients and their families with the combination of high-risk localized prostate cancer and a strong family history of specific cancers (breast, ovarian, pancreas, GI tumors, lymphoma)
- Future directions include randomized trials to inform the proper role of focal ablative technology, new imaging modalities, and digital tools to facilitate shared decision-making
A complete summary of the new AUA localized prostate cancer guidelines can be found: http://www.auanet.org/guidelines/clinically-localized-prostate-cancer-new-(aua/astro/suo-guideline-2017)
Presented By: Mary Taplin, MD, Dana Farber Cancer Institute, Boston, MA
Written By: Benjamin T. Ristau, MD, Fox Chase Cancer Center, Philadelphia, PA
at the 2017 AUA Annual Meeting - May 12 - 16, 2017 – Boston, Massachusetts, USA